Posted inBiotechnology
Chutes & Ladders—FDA’s principal deputy to depart agency
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…
Posted inBiotechnology
Omeros antibody improves overall survival by 68% in rare condition, new analysis finds
Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a…
Posted inBiotechnology
Merck’s HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies
After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead’s lenacapivir, Merck & Co.'s islatravir…
Posted inBiotechnology
VC firm pens $608M biobucks deal to redirect NGM’s MASH drug to rare disease
KdT Ventures has signed off on a $608 million biobucks deal for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction associated steatohepatitis (MASH)…
Posted inBiotechnology
Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial
A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial,…
Posted inBiotechnology
Vertex’s pain trial hits endpoint but sinks stock as placebo comparison spooks investors
Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval…
Posted inBiotechnology
Former Seagen CEO’s biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic
Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in…
Posted inBiotechnology
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer’s prospects
Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 million…
Posted inBiotechnology
Roche reports failure of Prothena-partnered Parkinson’s prospect in phase 2b but highlights positives
Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein. Days after UCB reported the…
Posted inBiotechnology
Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities
Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million upfront to help bypass…